@article { WOS:000292892300018, title = {Backbone Cyclic Peptide Inhibitors of Protein Kinase B (PKB/Akt)}, journal = {JOURNAL OF MEDICINAL CHEMISTRY}, volume = {54}, year = {2011}, note = {[[{"fid":"263845","view_mode":"default","type":"media","attributes":{"style":"width: 350px; height: 173px;","alt":"back","class":"img-responsive media-element file-default"}}]]}, month = {JUL 28}, pages = {5154-5164}, abstract = {

Elevated levels of activated protein kinase B (PKB/Akt) have been detected in many types of cancer. Substrate-based peptide inhibitors have the advantage of selectivity due to their extensive interactions with the kinase-specific substrate binding site but often lack necessary pharmacological properties. Chemical modifications of potent peptide inhibitors, such as cyclization, may overcome these drawbacks while maintaining potency. We present an extensive structure-activity relationship (SAR) study of a potent peptide-based PKB/Akt inhibitor. Two backbone cyclic (BC) peptide libraries with varying modes of cyclization, bridge chemistry, and ring size were synthesized and evaluated for in vitro PKB/Akt inhibition. Backbone-to-backbone urea BC peptides were more potent than N-terminus-to-backbone amide BC peptides. Several analogues were up to 10-fold more active than the parent linear peptide. Some activity trends could be rationalized using computational surface mapping of the PKB/Akt kinase catalytic domain. The novel molecules have enhanced pharmacological properties which make them promising lead candidates.

}, issn = {0022-2623}, doi = {10.1021/jm2003969}, author = {Tal-Gan, Yftah and Mattan Hurevich and Klein, Shoshana and Avraham Ben-Shimon and Rosenthal, David and Hazan, Carina and Deborah E. Shalev and Niv, Masha Y. and Levitzki, Alexander and Gilon, Chaim} }